PSCI-18-092 |
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) |
PSCI-18-109 |
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors |
PSCI-18-112 |
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC) |
PSCI-18-131 |
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis |
PSCI-18-143 |
Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR |
PSCI-19-021 |
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS) |
PSCI-19-039 |
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination with either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors |
PSCI-19-044 |
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer |
PSCI-19-047 |
Phase 1/2 Study to Evaluate Palbociclib (Ibrance?) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors |
PSCI-19-049 |
AGCT1532, Randomized Phase 3 Trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastic Germ Cell Tumors |